AbbVie Inc. Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities
AbbVie Inc. (ABBV) reported Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities of $222.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-20.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities · last filed 2026-02-20
- AbbVie Inc. unrecognized tax benefits, decrease resulting from settlements with taxing authorities for fiscal 2025 was $222.00M, a 21.83% decline from fiscal 2024.
- AbbVie Inc. unrecognized tax benefits, decrease resulting from settlements with taxing authorities for fiscal 2024 was $284.00M, a 230.23% increase from fiscal 2023.
- AbbVie Inc. unrecognized tax benefits, decrease resulting from settlements with taxing authorities for fiscal 2023 was $86.00M, a 1128.57% increase from fiscal 2022.
- AbbVie Inc. unrecognized tax benefits, decrease resulting from settlements with taxing authorities for fiscal 2022 was $7.00M, a 70.83% decline from fiscal 2021.
| Period end | Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities 12 month |
|---|---|
| 2025-12-31 | $222.00M 10-K · filed 2026-02-20 |
| 2024-12-31 | $284.00M 10-K · filed 2026-02-20 |
| 2023-12-31 | $86.00M 10-K · filed 2026-02-20 |
| 2022-12-31 | $7.00M 10-K · filed 2025-02-14 |
| 2021-12-31 | $24.00M 10-K · filed 2024-02-20 |
| 2020-12-31 | $141.00M 10-K · filed 2023-02-17 |
| 2019-12-31 | $749.00M 10-K · filed 2022-02-18 |
| 2018-12-31 | $79.00M 10-K · filed 2021-02-19 |
| 2017-12-31 | $233.00M 10-K · filed 2020-02-21 |
| 2016-12-31 | $0.00 10-K · filed 2019-02-27 |
| 2015-12-31 | $0.00 10-K · filed 2018-02-16 |
| 2012-12-31 | $50.00M 10-K · filed 2015-02-20 |
| 2011-12-31 | $430.00M 10-K · filed 2014-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |